Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 1:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Systemic Diseases Clear all
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA

NCT03712345
View directory record Official record
Conditions
Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA)
Interventions
IFX-1 low dose, IFX-1 high dose, Placebo
Drug
Lead sponsor
InflaRx GmbH
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
33
States / cities
Scottsdale, Arizona • Loma Linda, California • Doral, Florida + 30 more
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Sep 22, 2026, 1:13 PM EDT
Recruiting Phase 2Phase 3 Interventional

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

NCT06328777
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma, Interstitial Lung Diseases
Interventions
CABA-201
Biological
Lead sponsor
Cabaletta Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
10
States / cities
New Haven, Connecticut • Jacksonville, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 22, 2026, 1:13 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effect of Sublingually Generated S-nitroso-N-acetylcysteine on Systemic Blood Pressure.

NCT05798481
View directory record Official record
Conditions
Hypertension, Cardiovascular Diseases
Interventions
Mixture of Sodium Nitrite and N-acetylcysteine (NAC) crytals.
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 22, 2026, 1:13 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of AT-02 in Subjects With Systemic Amyloidosis.

NCT05951049
View directory record Official record
Conditions
Amyloidosis; Systemic
Interventions
AT02
Drug
Lead sponsor
Attralus, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Kansas City, Kansas • Cleveland, Ohio • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 22, 2026, 1:13 PM EDT
Completed No phase listed Observational

Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)

NCT01475149
View directory record Official record
Conditions
Antiphospholipid Syndrome, Thrombophilia Due to Antiphospholipid Antibody, Systemic Lupus Erythematosus
Interventions
Phlebotomy
Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Sep 22, 2026, 1:13 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

The Efficacy of Systemic Valacyclovir (Valtrex) on Periodontitis

NCT05712343
View directory record Official record
Conditions
Severe Periodontitis
Interventions
Valacyclovir group, Control group
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Sep 22, 2026, 1:13 PM EDT
Terminated Phase 3 Interventional

Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis

NCT05288855
View directory record Official record
Conditions
Adolescent Lupus Nephritis, Pediatric Lupus Nephritis
Interventions
Voclosporin, Placebo Oral Capsule
Drug
Lead sponsor
Aurinia Pharmaceuticals Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 22, 2026, 1:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability

NCT03063489
View directory record Official record
Conditions
Eye Pain
Interventions
Loteprednol Etabonate Ophthalmic Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
6
States / cities
Phoenix, Arizona • Oceanside, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Sep 22, 2026, 1:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants

NCT01576003
View directory record Official record
Conditions
Bloodstream Infections, Short Bowel Syndrome, Development, Nutrition, Biological Markers
Interventions
Glutamine, L-alanine
Drug · Dietary Supplement
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Weeks to 12 Months
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
2
States / cities
Ann Arbor, Michigan • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Sep 22, 2026, 1:13 PM EDT
Completed Phase 1 Interventional

Cyclophosphamide and Fludarabine to Treat Lupus Nephritis

NCT00001676
View directory record Official record
Conditions
Glomerulonephritis, Lupus Nephritis, Systemic Lupus Erythematosus
Interventions
SQ Fludarabine
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 22, 2026, 1:13 PM EDT
Completed Not applicable Interventional

CoQ10 Biomarker Trial

NCT01408680
View directory record Official record
Conditions
Oxidative Stress, Inflammation, Endothelial Dysfunction
Interventions
Coenzyme Q10, Placebo
Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 85 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Sep 22, 2026, 1:13 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus

NCT02391259
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
AMG 557, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
12
States / cities
Anniston, Alabama • Phoenix, Arizona • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2015 · Synced Sep 22, 2026, 1:13 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Effect of Leukoreduced Blood Transfusions on Infection Following Trauma

NCT00135291
View directory record Official record
Conditions
Wounds and Injuries
Interventions
Leukoreduced blood transfusion
Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 10, 2008 · Synced Sep 22, 2026, 1:13 PM EDT
Completed Phase 2 Interventional Results available

CM4620 Injectable Emulsion Versus Supportive Care in Patients With Acute Pancreatitis and SIRS

NCT03401190
View directory record Official record
Conditions
Acute Pancreatitis, Systemic Inflammatory Response Syndrome
Interventions
CM4620 Injectable Emulsion (Low Dose), CM4620 Injectable Emulsion (High Dose)
Drug
Lead sponsor
CalciMedica, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Detroit, Michigan • Minneapolis, Minnesota • Saint Paul, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 22, 2026, 1:13 PM EDT
Completed Phase 1 Interventional

CellCept in p-ANCA Vasculitis

NCT00405860
View directory record Official record
Conditions
MPO-ANCA Vasculitis, Microscopic Polyangiitis
Interventions
CellCept (mycophenolate mofetil)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 22, 2011 · Synced Sep 22, 2026, 1:13 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma

NCT00003388
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, cyclophosphamide, cytarabine, methotrexate, pegylated liposomal doxorubicin hydrochloride, prednisone, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
5
States / cities
Palo Alto, California • Stanford, California • Perth Amboy, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 22, 2026, 1:13 PM EDT
Completed Not applicable Interventional

Multicenter Blood Culture Quality Improvement

NCT01413555
View directory record Official record
Conditions
Bacteremia
Interventions
Blood Culture QI Program
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
14,889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Sep 22, 2026, 1:13 PM EDT
Completed No phase listed Observational

Improved Detection of Neonatal Sepsis Using a Targeted Biomarker Assay

NCT01120678
View directory record Official record
Conditions
Neonatal Sepsis
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
3 Days and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Sep 22, 2026, 1:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Atherosclerosis in Rheumatoid Arthritis and Lupus: Restoring Cholesterol Balance

NCT01180361
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2025
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 22, 2026, 1:13 PM EDT
Not listed Phase 3 Interventional

Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia

NCT00020865
View directory record Official record
Conditions
Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma, Neutropenia, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cefepime hydrochloride, levofloxacin
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 22, 2026, 1:13 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

NCT00403767
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Embolism
Interventions
Rivaroxaban, Warfarin, Matching placebo for Rivaroxaban arm (Warfarin placebo), Matching placebo for Warfarin arm (Rivaroxaban placebo)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
14,269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
295
States / cities
Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 292 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Sep 22, 2026, 1:13 PM EDT
Completed No phase listed Observational

Study of the Predictors of the Course and Early Outcome of Patients With Systemic Lupus Erythematosus: Nature Versus Nurture

NCT00006134
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1993
U.S. locations
3
States / cities
Birmingham, Alabama • Galveston, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 22, 2026, 1:13 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma

NCT00426764
View directory record Official record
Conditions
Peripheral T-cell Lymphoma
Interventions
Romidepsin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
45
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Sep 22, 2026, 1:13 PM EDT
Completed Not applicable Interventional

Acute Effect of Systemic Stress on Measured Blood Concentrations of 25 (OH) Vitamin D

NCT02460211
View directory record Official record
Conditions
Cardiovascular Disease, Vitamin D Deficiency
Interventions
Vitamin D3, Placebo
Dietary Supplement
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Apr 4, 2021 · Synced Sep 22, 2026, 1:13 PM EDT